An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fed condition
Latest Information Update: 18 Mar 2026
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Sun Pharmaceutical Industries
Most Recent Events
- 18 Mar 2026 New trial record